[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 1997

Prognostic Factors for Clinical Response of Alopecia Areata to Topical Immunotherapy With Squaric Acid Dibutylester

Author Affiliations

Department of Dermatology Naiseikai General Hospital 3 3-10 Futaba-dai, Mito Ibaraki 311-41, Japan

Tsukuba, Japan

Arch Dermatol. 1997;133(4):539-540. doi:10.1001/archderm.1997.03890400145035

Squaric acid dibutylester (SADBE) is a strong topical sensitizer that lacks mutagenic properties. It has been used as an allergen in the topical therapy of patients with alopecia areata, with 50% to 90% of such patients responding.1-5 Since SADBE immunotherapy usually requires a prolonged period of treatment, it would be helpful to know which factors affect treatment outcome. Several previous studies1-4 mention some factors, but most of them lack detailed statistical comparisons of patients' responses to therapy with regard to prognostic factors. Thus, we investigated the efficacy of topical immunotherapy with SADBE in patients with alopecia areata using an uncontrolled study and evaluated the relative importance of various prognostic factors in treatment outcome.

Materials and Methods.  A total of 48 patients (16 males and 32 females; age range, 6-57 years) with alopecia areata involving more than 25% of the scalp were evaluated. They included 31 patients with patchy

First Page Preview View Large
First page PDF preview
First page PDF preview